Can I start brexpiprazole (Braylar) 1.5 mg while tapering lithium 600 mg daily?

Can You Add Brexpiprazole 1.5 mg While Tapering Lithium?

Yes, you can add brexpiprazole 1.5 mg while tapering lithium, but this requires a clear clinical rationale for the medication combination, close monitoring, and a structured transition plan. The combination is feasible during a cross-titration period, though guidelines emphasize the need for specific justification when using antipsychotic-mood stabilizer combinations 1.

Clinical Framework for This Transition

Rationale Requirements

Before implementing this combination, establish why both medications are needed simultaneously 1:

• Treating multiple conditions (e.g., bipolar disorder with psychotic features requiring both mood stabilization and antipsychotic coverage)
• Bridging therapy during lithium discontinuation to prevent symptom breakthrough
• Treatment-resistant symptoms where monotherapy has proven inadequate

The 2009 AACAP guidelines explicitly state that medication combinations require a treatment and monitoring plan, patient/family education, and clear documentation of the rationale 1.

Dosing Considerations

Brexpiprazole 1.5 mg is below the typical therapeutic range:

• For schizophrenia: target dose is 2-4 mg/day 2, 3
• For depression augmentation: target dose is 2 mg/day 4, 5, 3
• Brexpiprazole requires 1-2 week titration to target dose 2

This sub-therapeutic dose suggests you're either:

1. In the titration phase (appropriate)
2. Using a maintenance dose that may be inadequate for full therapeutic effect

Monitoring During Combination Therapy

Laboratory monitoring is essential given lithium's narrow therapeutic index 6, 7:

• Serum lithium levels should remain below 1.5 mEq/L to minimize toxicity risk 7
• Monitor for early lithium toxicity signs: diarrhea, vomiting, drowsiness, muscular weakness, lack of coordination 7
• Check renal function, as lithium requires adequate renal clearance 7

Watch for additive side effects:

• Both medications can cause sedation and weight gain 2, 3
• Brexpiprazole may cause akathisia (though less than aripiprazole) 2, 3
• Monitor for metabolic changes and extrapyramidal symptoms

Tapering Strategy

If transitioning from lithium to brexpiprazole:

1. Start brexpiprazole at low dose (0.5-1 mg) and titrate up over 1-2 weeks while lithium is still at therapeutic levels 2
2. Once brexpiprazole reaches target dose (2-4 mg for psychosis, 2 mg for mood), begin gradual lithium taper
3. Taper lithium slowly to monitor for symptom breakthrough - WHO guidelines recommend maintenance treatment for at least 2 years after the last bipolar episode 6
4. Avoid abrupt lithium discontinuation as this increases relapse risk 6

Critical Caveats

Lithium contraindications matter 7:

• Do not use lithium with significant renal/cardiovascular disease, severe debilitation, dehydration, or sodium depletion
• Concurrent diuretic use dramatically increases lithium toxicity risk
• If these conditions exist, prioritize transitioning off lithium more urgently

Antipsychotic polypharmacy concerns:

• Guidelines generally recommend monotherapy when possible 6, 8
• The 2021 review on antipsychotic polypharmacy notes it's used in 10-40% of patients despite guideline recommendations against it 8
• Combination therapy is most justified for treatment-resistant cases or during medication transitions 1

Drug Interactions

Brexpiprazole is metabolized by CYP2D6 and CYP3A4 2, 9:

• Check for other medications that inhibit or induce these enzymes
• Dose adjustments may be needed with hepatic/renal impairment 3
• Recent research shows brexpiprazole itself affects hepatic CYP enzymes after prolonged use 9

Practical Algorithm

1. Document clear rationale for combination (not just convenience)
2. Ensure lithium monitoring is in place (levels, renal function, thyroid)
3. Start/continue brexpiprazole at current dose with plan to reach 2-4 mg
4. Monitor weekly initially for efficacy and side effects
5. Begin lithium taper only after brexpiprazole reaches therapeutic dose and patient is stable
6. Taper lithium gradually (reduce by 25% every 1-2 weeks as a general approach)
7. Continue close monitoring for 2-3 months post-lithium discontinuation

The combination itself is not contraindicated, but the clinical context, monitoring plan, and transition strategy determine whether this approach prioritizes patient safety and optimal outcomes.